The application of the modern target medications for the treatment of metastatic colorectal cancer

作者: D. A. Andreev , A. A. Zav'yalov , K. A. Kokushkin , M. V. Davydovskaya

DOI: 10.17116/DOKGASTRO20187221

关键词:

摘要:

参考文章(42)
Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Parkin, David Forman, Freddie Bray, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. ,vol. 136, ,(2015) , 10.1002/IJC.29210
James E. Krook, Charles G. Moertel, Leonard L. Gunderson, Harry S. Wieand, Roger T. Collins, Robert W. Beart, Theodore P. Kubista, Michael A. Poon, William C. Meyers, James A. Mailliard, Donald I. Twito, Roscoe F. Morton, Michael H. Veeder, Thomas E. Witzig, Stephen Cha, Subhash C. Vidyarthi, Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma New England Journal of Medicine. ,vol. 324, pp. 709- 715 ,(1991) , 10.1056/NEJM199103143241101
H. S. Hochster, N. Uboha, W. Messersmith, P. J. Gold, B. H. ONeil, D. Cohen, C. Denlinger, S. Cohen, C. G. Leichman, L. Leichman, Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer Cancer Chemotherapy and Pharmacology. ,vol. 75, pp. 17- 23 ,(2015) , 10.1007/S00280-014-2609-3
Scott M. Wilhelm, Jacques Dumas, Lila Adnane, Mark Lynch, Christopher A. Carter, Gunnar Schütz, Karl-Heinz Thierauch, Dieter Zopf, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity International Journal of Cancer. ,vol. 129, pp. 245- 255 ,(2011) , 10.1002/IJC.25864
Dae Dong Kim, Cathy Eng, The current state of targeted agents in rectal cancer. International Journal of Surgical Oncology. ,vol. 2012, pp. 406830- 406830 ,(2012) , 10.1155/2012/406830
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, Norbert Niederle, Andreas Rost, Heinz-Gert Höffkes, Markus Moehler, Reinhard U Lindig, Dominik P Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncology. ,vol. 15, pp. 1065- 1075 ,(2014) , 10.1016/S1470-2045(14)70330-4
J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, S Koski, K Rittweger, F Gilberg, L Saltz, XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results British Journal of Cancer. ,vol. 105, pp. 58- 64 ,(2011) , 10.1038/BJC.2011.201
Kristen K. Ciombor, Jordan Berlin, Aflibercept—a Decoy VEGF Receptor Current Oncology Reports. ,vol. 16, pp. 368- 368 ,(2014) , 10.1007/S11912-013-0368-7
Pinaki R. Dutta, Amit Maity, Cellular responses to EGFR inhibitors and their relevance to cancer therapy Cancer Letters. ,vol. 254, pp. 165- 177 ,(2007) , 10.1016/J.CANLET.2007.02.006
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 360, pp. 1408- 1417 ,(2009) , 10.1056/NEJMOA0805019